According to the announcement, KPC announced that in the first half of 2026, it achieved operating income of 1,643 billion yuan, a year-on-year decrease of 50.97%; net loss attributable to shareholders of listed companies was 364 million yuan, a year-on-year decrease of 283.48%; net loss after deducting non-recurring profit and loss of 390 million yuan, a year-on-year decrease of 358.30%. Basic earnings per share -$0.48. There will be no profit distribution during the reporting period, and no capital transfer from the Provident Fund will be implemented. The decline in performance was mainly affected by a combination of external factors such as the expansion of proprietary Chinese medicine collection and market diversion, as well as internal factors such as the implementation of marketing model reforms falling short of expectations, declining capacity utilization, and increased credit impairment losses.

According to the announcement, KPC announced that in the first half of 2026, it achieved operating income of 1,643 billion yuan, a year-on-year decrease of 50.97%; net loss attributable to shareholders of listed companies was 364 million yuan, a year-on-year decrease of 283.48%; net loss after deducting non-recurring profit and loss of 390 million yuan, a year-on-year decrease of 358.30%. Basic earnings per share -$0.48. There will be no profit distribution during the reporting period, and no capital transfer from the Provident Fund will be implemented. The decline in performance was mainly affected by a combination of external factors such as the expansion of proprietary Chinese medicine collection and market diversion, as well as internal factors such as the implementation of marketing model reforms falling short of expectations, declining capacity utilization, and increased credit impairment losses.